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Enhanced cytocompatibility and functional group
content of poly(L-lysine) dendrimers by grafting
with poly(oxazolinesQ1 )†
R. M.Q2 England,a,b J. I. Hare,a P. D. Kemmitt,a K. Treacher,b M. J. Waring,a S. T. Barry,a
C. Alexanderc and M. AshfordQ3 b
When considering the design of an advanced drug delivery system, a common desirable attribute is to
have a prolonged residence time in blood circulation so that accumulation and localised payload release
may occur at the site of interest (e.g. a tumour). Polyethylene glycol (PEG) has been a gold standard for
fulfilling this requirement, and consequently has been well investigated as a material for surface modifi-
cation of dendrimers. As an alternative, we have explored the use of polyoxazolines (POZ)s as materials
for modifying the surface of a generation 5 L-lysine dendrimer and found that there was a significant
improvement in the biocompatibility properties over the unmodified dendrimer. One particularly useful
advantage of POZ over PEG lies in the main-chain pendant groups available that we were able to exploit
to impart functionality. Modifying the POZ to have pendant carboxyl groups led to a novel modified den-
drimer with significantly more sites for conjugation. With this, we have demonstrated a sixfold increase in
the loading of coumarin (our model compound) when compared to a non-functional POZ equivalent.
Introduction
Dendrimer-drug conjugates, typically in the range of 2–25 nm
in size, are increasingly popular as drug delivery systems
because they are water soluble, have near-monomodal mole-
cular weight distributions, reproducible synthesis steps and
have large numbers of surface groups available for drug conju-
gation. In addition, these accessible functional groups can be
easily modified for property enhancement, for example by sub-
stitution with PEG chains to reduce cytotoxicity and systemic
clearance. PEGylation has been widely employed with poly-
amidoamine (PAMAM)1–4 and poly(L-lysine) dendrimers.5–8
The circulation time of these cationic dendrimers is signifi-
cantly improved when modified with PEG as the surface
charge is neutralised and PEG tends to have low reticuloen-
dothelial system uptake and low immunogenicity. These types
of drug delivery systems can also benefit from accumulation at
the site of interest (e.g. a tumour via the Enhanced Permeation
and Retention (EPR) effect) allowing for desirable localised
drug delivery.9 However, the relative inertness of PEG can also
be disadvantageous, as it is difficult to functionalise PEG itself
with components like targeting ligands. To improve the diver-
sity and functionality of these derivatised poly(amine) dendri-
mer systems we chose to use POZs as an alternative material to
modify the dendrimer surface. POZs have become popular
alternatives to PEG, in-part owing to the diversity offered by
the pendant group that could in turn be derivatised to a wide
range of different functionalities with many different resulting
polymer properties.10–12 Furthermore, the implementation of
microwave synthesis for POZs has significantly improved reac-
tion rates whilst maintaining living polymerisation, leading to
well-defined polymers with facile introduction of chain-end
functionality.13–15 POZs have been reported to have similar
stealth and biocompatibility properties to PEG16–18 and thus
have been widely used in the field of investigational polymer
therapeutics.19–22 With this in mind we considered two of the
most widely used types of POZ for bioapplications; poly(2-
methyl-2-oxazoline) (PMOx) and poly(2-ethyl-2-oxazoline)
(PEOx) for the surface modification of a generation 5 L-lysine
dendrimer. The attraction of this system lies in the fine-tuning
of the properties that could be achieved by using POZ through
main-chain and end group variation e.g. improved water solu-
bility and improved viscosity properties. In this manuscript,
the most important main-chain variation that we have explored
is a POZ with a pendant ester group that was synthesized and
used to modify pre-formed lysine dendrimers. Subsequent de-
protection of the ester groups yielded carboxyl functionalities
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along the backbone and therefore significantly more sites for
drug conjugation than currently available using existing PEG
and PMOx/PEOx modified dendrimers. Without these
additional conjugation sites these types of dendrimers are
limited to the remaining (lysine) functional groups from the
dendrimer scaffold. These novel dendrimer types have been
explored for properties which would underlie their potential
application as drug delivery systems using a model compound
(coumarin) to conjugate to the dendrimers as a proof-of-prin-
ciple experiment to test drug loading and cytocompatibility.
Materials and methods
Materials
All reagents and solvents were purchased from Sigma Aldrich
with exception of MeO-PEG-COOH (2000 Da) (Iris Biotech
GMBH), Boc-L-Lys(Boc)-ONp & 2-chloro-4,6-dimethoxy-1,3,5-tri-
azine (Chem-Impex International), 2-chloroethylamine hydro-
chloride (Fluorochem Inc.), sodium methoxide 5.4 M (Acros
Organics), Fetal calf serum (PAA), NucView™ (Biotium). Sartor-
ius AG VivaFlow® 50 cassettes (30 kDa MWCO) were purchased
from VWR. Polyethylene oxide standards were purchased from
Agilent Technologies as a kit. Wistar rat heparinized whole
blood was ordered fresh from Harlan Laboratories UK Ltd and
used the same day.
Equipment
1H NMR analysis was performed on a Bruker AV400. Gel Per-
meation Chromatography-Refractive Index (GPC)-RI was per-
formed on a Malvern TDA302 with either an Agilent
Technologies aquagel-OH-20 column running 50/50 MeOH/
40 : 10 mM NaNO3 : NaH2PO4 as the eluent or a Tosoh Bio-
science TSKgel GMPWxl column with 40 : 10 mM NaNO3 :
NaH2PO4 as the eluent. The system calibration was performed
using a single poly(ethylene oxide) standard (16 100 g mol−1)
and absolute molecular weights determined using the refrac-
tive index and light scattering signals. Organic GPC was per-
formed with DMF (0.05 M LiBr) and a universal calibration
using PEG/PEO narrow standards ranging from 194 g mol−1 to
16 100 g mol−1. GPC-UV was performed on a Waters HP1100
fitted with a Tosoh Bioscience TSKgel GMPWxl column with
PBS as the eluent and UV detection at 220 nm. Haemoglobin
levels were recorded using a HemoCue® Hb210 and HemoCue
plasma/low Hb system for high and low hemoglobin concen-
tration measurements. Samples were centrifuged in a Eppen-
dorf™ MiniSpin™ microcentrifuge. Dynamic light scattering
was performed on a Malvern Zetasizer® at a temperature of
25 °C. Samples were made to concentrations of 5 mg mL−1 in
10 mMolar NaCl solution or a 40 : 10 mMolar ratio of NaNO3 :
NaH2PO4 at pH 7.4 and were filtered using a 0.2 μm syringe
filter prior to measurement. Data was obtained using Malvern
Zetasizer software version 6.21J. Haemoaggregation was
measured on a Zeiss Axio Scope. A1 at 40× magnification.
Images were taken with an integrated Zeiss Axio Cam ERc 5 s
camera and manipulated with Zeiss ZEN Lite 2011 software.
Methods
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium
chloride and tetrafluoroborate. DMTMM·Cl23 and
DMTMM·BF4
24 were synthesised according to methods
reported previously.
N-(2-Aminoethyl)-2-oxo-2H-chromene-3-carboxamide (cou-
marin-NH2). Coumarin-3-carboxylic acid (200 mg, 1.05 mmol)
and DMTMM·BF4 (518 mg, 1.58 mmol) were weighed into a
reaction vial. DMF (5 mL) was added, followed by tert-butyl
(2-aminoethyl)carbamate (253 mg, 1.58 mmol) dissolved in
anhydrous DMF (0.5 mL). The reaction was followed to com-
pletion by UPLC-MS (approximately 30 min). The reaction
mixture was diluted with EtOAc (20 mL), and washed with
saturated NaHCO3 (2 × 10 mL) and saturated brine (2 ×
10 mL). The organic layer was dried over MgSO4, filtered and
evaporated to afford crude product, which was purified by
flash silica chromatography, elution gradient 20 to 70% 3 : 1
EtOAc/EtOH in heptane to give tert-butyl (2-(2-oxo-2H-chro-
mene-3-carboxamido)ethyl)carbamate (264 mg, 76%). The boc-
deprotecting group was removed by stirring the solid in DCM
(7.5 mL) and TFA (1 mL, 16 eq.) for 4 h and removing the sol-
vents under vacuum at room temperature overnight to give the
title compound. Yield = 275 mg, 100% (TFA salt). MS ES+ =
333.3 (analytical ESI S2 Fig. 1–4†).
Generation 5 L-lysine dendrimer. The dendrimer was syn-
thesised to generation 2 according to a literature method.25
Successive generations were synthesised from repetitive steps
involving the deprotection of the previous generation’s lysine
boc-protecting groups using trifluoroacetic acid (50 eq. to boc
groups) in DCM (10× volume) followed by partial evaporation
and precipitation into 20× excess of diethyl ether. A white solid
was obtained through filtration and overnight drying in a
vacuum oven. Further reaction with Boc-L-Lys(Boc)-Onp in the
presence of triethylamine produced the next generation boc-
protected dendrimer. Reaction times, equivalents of reagents
and yields are summed up in ESI S1 Table 1.† 1H NMR and
MALDI-TOF-MS ESI S2 Fig. 5.†
HOOC-poly(2-methyl-2-oxazoline)-OMe (1a). Freshly distilled
2-methyl-2-oxazoline (2 g, 23.5 mmol) (over CaH2, N2) was
added to an oven-dried, nitrogen-purged microwave tube fitted
with a septum. Anhydrous acetonitrile (4 mL) was added via
syringe, followed by tert-butyl bromoacetate (0.195 g, 1 mmol).
The reaction mixture was transferred to a microwave reactor
and heated to 140 °C for 30 min. The solution was cooled to
0 °C using an ice bath and then sodium methoxide solution
(2 M, 2.5 mL, 5 eq.) was added dropwise and then stirred for
10 minutes at 0 °C. Sodium hydroxide solution (2 M, 2 mL)
was added and the reaction mixture was stirred overnight at rt.
The reaction mixture was acidified to pH 5 using HCl (2 M)
and then the solvents were removed by rotary evaporation.
Anhydrous ethanol (dried over 3A molecular sieves) (15 mL)
was added and the flask agitated under a nitrogen blanket
until the polymer had dissolved leaving behind the NaCl salts
which were filtered off. The ethanol was evaporated and the
process repeated. The polymer was dissolved in a minimum
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volume of anhydrous ethanol and was added to a large volume
of diethyl ether (400 mL), filtered and dried under vacuum. To
remove traces of ethanol the polymer was freeze-dried to
obtain the title compound as a white solid. Yield = 1.9 g, 89%.
1H NMR ESI S2 Fig. 6.†
HOOC-poly(2-ethyl-2-oxazoline)-OMe (1b). This compound
was synthesised following the method for 1a, but in place of
anhydrous ethanol, anhydrous DCM was used to remove the
unwanted NaCl salts. The polymer was obtained as a white
solid after precipitation into diethyl ether, filtering and drying
overnight under vacuum at 40 °C. Yield = 1.74 g, 83%. 1H NMR
ESI S2 Fig. 7.†
MeO-PEG-COOH (2000 Da) (1c). This polymer was pur-
chased from Iris Biotech GMBH. 1H NMR ESI S2 Fig. 8.†
Methyl 4-(2-chloroethyl)amino)-4-oxobutanoate. This com-
pound was synthesised according to the literature26 using
methyl 4-chloro-4-oxobutyrate (8 g, 53.13 mmol) to give the
title compound (6.92 g, 67.3%) as a yellow oil. The crude
product was used without further purification.
Methyl 3-(4,5-dihydrooxazol-2-yl)propanoate. Methyl 4-((2-
chloroethyl)amino)-4-oxobutanoate (6.9 g, 35.64 mmol) and
anhydrous sodium carbonate (2.83 g, 26.73 mmol) were mixed
under vacuum at 0.5 mbar and gradually heated to 157 °C in a
Kugelrohr apparatus. The title compound distilled off as a col-
ourless oil and was collected and used immediately. Yield =
2.70 g, 48.2%.
HOOC-poly(methyl-4-oxobutanoate-2-oxazoline)-ethyl-2-
thioethanoate (HOOC-PEsterOx-COOMe) (1d). Methyl 3-(4,5-
dihydrooxazol-2-yl)propanoate (2.7 g, 17.18 mmol) was added
to an oven-dried, nitrogen-purged microwave tube fitted with a
stirrer bar and septum. Anhydrous acetonitrile (5 mL) was
added, followed by tert-butyl bromoacetate (0.181 mL,
1.23 mmol). The reaction mixture was transferred to a Biotage
microwave and heated to 140 °C for 30 min. After cooling to rt,
ethyl thioglycolate (2 eq.) was added followed by anhydrous tri-
ethylamine (2 eq.) and stirred overnight. The reaction mixture
was added dropwise to rapidly stirring diethyl ether (250 mL)
to form a white precipitate that was filtered and dried under
vacuum. The solid was then taken up in DCM (100 mL) and
washed with saturated NaHCO3 (3 × 30 mL) before washing
with saturated brine (2 × 30 mL). The organic layer was dried
over magnesium sulphate, filtered and the solvents evapo-
rated. The film was taken up in DCM (25 mL) and TFA (4 mL)
was added dropwise and stirred for 5 h. The solvents were
removed under vacuum and the film was taken up in de-
ionised water (50 mL) before freeze-drying to give the title com-
pound as a white solid. Yield = 2.8 g, 90% 1H NMR ESI S2
Fig. 9.†
G5-PLL[PMOx-OMe]x[NH2]y (2a). The generation 5 L-lysine
dendrimer (100 mg, 6.53 μmol) and 1a (667 mg, 0.31 mmol, 48
eq.) were dissolved together in deionised water (5 mL).
DMTMM·Cl (174 mg, 0.63 mmol, 96 eq.) was added as a solid
and after dissolution the pH of the solution was adjusted to
∼8 using saturated NaHCO3 solution. The reaction mixture
was stirred at rt for 4d. The pH of the reaction was monitored
and maintained at 8. Afterwards, the reaction mixture was
acidified to pH 5 using HCl (2 M) and purified using a Viva-
Flow® cassette in deionised water (30 kDa MWCO) connected
to a peristaltic pump. Removal of unreacted POZ and
DMTMM·Cl was monitored by SEC-UV (220 nm) and the reac-
tion was typically free of low molecular weight impurities after
1–2 hours. The title compound was obtained as a white solid
after freeze-drying. Yield = 348 mg, 70%. (Yield calculated
according to a desired 50% modified polymer.)
G5-PLL[PEOx-OMe]x[NH2]y (2b). The method above was
used but with 1b in place of 1a. Yield = 343 mg, 69% 1H NMR
ESI S2 Fig. 10.†
G5-PLL[PEG-OMe]x[NH2]y (2c). The method for 2a was used
but with commercially available HOOC-PEG-OMe (1c). Yield =
373 mg, 79% 1H NMR ESI S2 Fig. 11.†
G5-PLL[P(2-ester-2-oxazoline)]x[NH2]y (2d). The generation 5
L-lysine dendrimer (100 mg, 6.53 μmol) and 1d (697 mg,
0.31 mmol, 48 eq.) were dissolved together in anhydrous DMF
(5 mL). DMTMM·BF4 (206 mg, 0.63 mmol, 96 eq.) was added
as a solid and after dissolution N-methyl morpholine (∼20 μL)
was added. The reaction was then stirred for 48 h at rt. The
reaction mixture was diluted with ethyl acetate (3 mL) and the
solution added to rapidly stirring diethyl ether (250 mL) to
form a white precipitate. The precipitate was filtered, dried
under vacuum and then taken up in deionised water (50 mL).
The pH was adjusted to 5 with HCl (2 M) and the polymer puri-
fied similarly to 2a. The title compound was obtained as a
white solid. Yield = 425 mg, 82%. 1H NMR ESI S2 Fig. 12.†
G5-PLL[PMOx-OMe]x[COOH]y (3a) and G5-PLL[P(2-ester-2-
oxazoline)]x[COOH]y (3d). The residual amine groups on 2a
and 2d were modified to acids using succinic anhydride.
Briefly, the dendrimer (200 mg, 0.08 mmol (NH2)) was dis-
solved in anhydrous methanol (4 mL). Succinic anhydride
(50.1 mg, 0.50 mmol, 6 eq. to NH2) was added as a solid, fol-
lowed by triethylamine (23 μL, 0.17 mmol, 64 eq.). The reaction
mixture was stirred at rt for 5 h before diluting with deionised
water (40 mL) and acidifying to pH 5 with HCl (0.1 M) and puri-
fying using VivaFlow® (30 kDa MWCO) for 1 hour. Both poly-
mers were obtained as white solids after freeze-drying. Yield 3a
= 174 mg, 74%. 3d = 195 mg, 94%. 1H NMR ESI S2 Fig. 13† (3a).
G5-PLL[P(2-acid-2-oxazoline)]x[COOH]y (4d). Polymer 3d
(150 mg, 1.70 mmol (ester repeat unit)) was dissolved in
methanol (3 mL). LiOH (42 mg, 2 eq. to each repeat unit) dis-
solved in deionised water (1 mL) was added dropwise and the
reaction mixture was stirred overnight at rt. The pH was
adjusted to 8 before removing the solvent under vacuum. The
solid was taken up in deionised water (20 mL) and the pH
adjusted to 4–5 to form a white precipitate that became a gum
on stirring. The water was decanted to waste and the gum
washed with deionised water (20 mL) before freeze-drying the
gum to obtain the title compound as a white solid. Yield =
111 mg, 89%. 1H NMR ESI S2 Fig. 14.†
G5-PLL[PMOx-OMe]x[coumarin]y (4a). Polymer 3a (50 mg,
0.62 μmol) was dissolved in anhydrous DMF (2 mL) in a nitro-
gen purged reaction tube fitted with a stirrer bar and septum.
DMTMM·BF4 (9.8 mg, 0.03 mmol) was added and the solution
stirred for 5 min. A preprepared solution of coumarin-NH2
Polymer Chemistry Paper
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(8.62 mg, 0.02 mmol, 40 eq.) in anhydrous DMF (0.5 mL) was
added via syringe. Triethylamine (3.5 μl, 0.02 mmol) in DMF
(0.2 mL) was added and the reaction mixture was stirred at rt
for 24 hours. The solution was then diluted with EtOAc (2 mL)
and precipitated into diethyl ether (200 mL). The precipitate was
collected, dried under vacuum and then dissolved in a 50/50
MeOH/water mixture (25 mL). The solution was passed through
a 0.45 μm filter and then purified by VivaFlow® (30 kDa MWCO)
gradually changing the eluent to pure deionised water. The title
compound was obtained as a white solid after freeze-drying.
Yield = 46 mg, 81%. 1H NMR ESI S2 Fig. 15.†
G5-PLL[P(2-acid-2-oxazoline)]x[coumarin]y (5d). This
polymer was prepared in a similar method as for 5a. Polymer
4c 50 mg, 0.56 μmol was dissolved in anhydrous DMF (2 mL)
in a nitrogen purged reaction tube fitted with stirrer bar and
septum. DMTMM·BF4 (35 mg, 0.11 mmol) was added and the
solution stirred for 5 min. Coumarin-NH2 (34 mg, 0.10 mmol)
was added as a solid directly and after dissolution, triethyl-
amine (14 μl, 0.10 mmol) in DMF (0.2 mL) was added slowly
drop-wise to avoid precipitation. The reaction mixture was
stirred at rt for 24 h before diluting with EtOAc (2 mL) and pre-
cipitating the product by addition to rapidly stirring diethyl
ether (200 mL). The precipitate was collected, dried under
vacuum and then dissolved initially in a small volume of
NaHCO3 solution (2 mL) and then diluted in a 50/50 MeOH/
water mixture (25 mL). The solution was passed through a
0.45 μm filter and then purified by VivaFlow® (30 kDa MWCO)
gradually changing the eluent to pure deionised water. The
title compound was obtained as a white solid after freeze-
drying. Yield = 54 mg, 78%. 1H NMR ESI S2 Fig. 16.†
Methodology for the cell viability and blood compatibility
Cell viability and proliferation assays. NIH 3T3 mouse fibro-
blasts were obtained from the Albert Wong Jefferson Cancer
Institute. Cells were cultured at 37 °C/5% CO2 in RPMI-1640,
supplemented with 10% fetal calf serum and 2 mM glutamine,
in the presence of penicillin–streptomycin. Cells were not used
beyond passage number 10 for these experiments. Cells were
seeded into 96-well plates at 5000 cells per well, in the pres-
ence of 1 µM NucView™ to enable the detection of apoptosis.
Seeded cells were allowed to adhere overnight. In triplicate,
the cells were treated with the modified dendrimers (except
dendrimer 2d which was not soluble enough to make a stock
solution) & unmodified L-lysine dendrimer at 0.5 mg mL−1
(final concentration) in full media. Plates were incubated at
37 °C in an IncuCyte™ FLR (Essen BioScience) and were
scanned every 4 hours for NucView™ fluorescence (apoptosis)
and cell confluence. The apoptosis induced by each dendrimer
was calculated relative to untreated controls and a maximum
value obtained from the unmodified L-lysine dendrimer at
96 hours.
Blood compatibility studies. The blood compatibility studies
were performed using Wistar rat blood collected in lithium
heparinised tubes. 250 µl of lithium heparinised whole blood
was placed in to a 1 ml Eppendorf tube and 250 µl of the
sample (4 mg ml−1 to measure at 2 mg ml−1) was added and
mixed gently for 45 seconds. 500 µl of physiological saline was
added to quench haemolysis and gently mixed. The tube was
placed into a centrifuge and spun at 600g for 5 minutes. A
sample of the supernatant was taken with a capillary stick, and
placed at the top of a micro-cuvette (plasma/low Hb) allowing
20 µl to be automatically drawn up by capillary action. The
cuvette was transferred to a Hemocue photometer (plasma/low
photometer) and the haemolysis measurement (released
haemoglobin, g dl−1) was taken. To measure the haemoaggrega-
tion, 100 μL of lithium heparinised whole blood was diluted
with 100 μL of sample in physiological saline (4 mg ml−1) and
gently mixed for 30 seconds. 20 μL of the mixture was trans-
ferred to a microscopy slide and a cover carefully placed on top.
The red blood cells were inspected at 40× magnification and
images were captured using the integrated Zeiss Axio camera.
Results and discussion
PMOx, PEOx and PEsterOx synthesis
POZs 1a and 1b (Scheme 1) were synthesised to have similar
chain end functional groups and molecular weight profiles to
the commercially available methoxy-poly(ethylene glycol)
(2000 g mol−1), which was used as a comparison in the dendri-
mer modifications.
Here we have compared polymers with average molecular
weights of ∼2000 g mol−1, but it is important to note that the
number of repeat units is different for each polymer at this
same molecular weight. The theoretical number of repeat
units for each polymer at this molecular weight decrease in the
order PEG > PMOx > PEOx > PEsterOx (n = 44, 23, 20, 14). The
use of PEG and POZ at ∼2000 g mol−1 was largely decided
from the literature where PEG has been extensively studied,
and comprehensively summarised by Kaminskas, Boyd and
Porter.6 Increasing the molecular weight beyond this would
only lead to a reduction in the maximum drug loading (weight
%) and make purification by ultrafiltration more difficult. The
POZs were all polymerized from freshly distilled monomer,
under anhydrous conditions to maintain a living polymeri-
sation and have low polydispersity. Sodium methoxide was
used to quench the polymerizations of PMOx and PEOx under
conditions designed not to cleave the amide bonds. Loss of
the tert-butyl ester protecting group at the initiator end after
treating with sodium methoxide indicated transesterification
had taken place as an unwanted side-reaction. Sodium hydrox-
ide solution was added after quenching to deprotect the newly
formed methyl ester. Full conversion of the monomer and
proof of the initiation from tert-butyl bromoacetate is demon-
strated in the 1H NMR spectra of the reaction mixture before
quenching (ESI S2 Fig. 17†) showing the tert-butyl ester peak
at 1.49 ppm and oxazolinium protons at 4.59 ppm and
5.01 ppm, which disappeared after addition of sodium
methoxide.
The ester POZ was not quenched with sodium methoxide
because the resulting methyl ester at the α-chain end could
not be hydrolysed without backbone esters also being cleaved.
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Instead, ethyl thioglycolate was used to quench the chain-end
providing an ethyl ester terminal group and preserving the
tert-butyl ester at the α-chain end. Ultimately the ethyl ester
provided another carboxyl group at the terminal chain-end
and yet another site for conjugation of coumarin. The syn-
thetic routes to the POZs are summarized in Scheme 1 and the
characteristics are summarized in Table 1.
POZ and PEG coupling to G5-PLL dendrimer. Polymers 1a–d
were used to modify the surface of the generation 5 L-lysine
dendrimer using the coupling agent 4-(4,6-dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium (DMTMM) in a random
modification i.e. some chains may have substituted onto
α-amines and others onto ε-amines. For PMOx, PEOx and PEG
the modifications were performed in aqueous conditions
using DMTMM chloride, which has been reported to be stable
in water for several days23 and a good option in sterically hin-
dered systems for which slow coupling is problematic. The
ester POZ (1d) had limited water solubility and the coupling
had to be performed in DMF with the tetrafluoroborate salt of
DMTMM, which is reported to be stable in organic solvent.24
VivaFlow® cassettes proved to be an efficient way to purify the
dendrimers and gave good yields (69–85%). The removal of the
excess linear POZ could be followed using HPLC-SEC-UV at
220 nm (example in ESI Fig. 18†). Following purification, the
removal of linear material was also confirmed by GPC (ESI
Fig. 19† showing an overlay of the linear PMOx and PMOx-
modified dendrimer). Previous attempts using dialysis (25 kDa
MWCO) for several days did not yield material free of linear
POZ or PEG (data not shown). When purified, the POZ coated
dendrimers had hydrodynamic diameters in the region of
8–10 nm as measured by DLS and high molecular weights
(79.5 kg mol−1 & 100.0 kg mol−1) with narrow polydispersities
(<1.1). The PEG modified dendrimer (2c) was found to be
slightly larger at 14 nm, which might be explained by the longer
chain length of PEG compared to the POZs (see Table 2).
Another explanation could be that there are more bound water
molecules to PEG than POZ given the differences in structure.
The polydispersity indices of the sub-9 nm particles were not
accurately determined due to interference in the intensity signal
on the DLS instrument which was not thought to be polymer
related. An interesting observation from the DLS data was that
the zeta potentials for 2a–c were almost neutral despite the
residual amines from the unmodified lysines of the dendrimer.
This suggests that the dendrimer surface was shielded by the
presence of the POZ and PEG. However, in the case of the 2d
there was a positive zeta potential measured that then became
negative after reacting the amines with succinic anhydride
(Table 2). This could be explained by the relatively poor solubi-
lity of the polymer driving a compacted conformation as well as
a shorter chain length (n = 16) compared to PEG (n = 44) and
PMOx (n = 24). The result is that the coverage was likely insuffi-
cient to mask the surface charge.
Biocompatibility studies. The Cytotoxicity studies were per-
formed in the presence of a fluorescent marker to measure
apoptosis. The fluorescence intensities indicated that at the
various time points of incubation, the POZ and PEG modified
dendrimers were undergoing much less apoptosis that the
unmodified dendrimer. For example, at 24 h there was 2–3%
of the cells undergoing apopotosis compared to 36% for the
unmodified dendrimer at a concentration of 0.5 mg mL−1
(mouse endothelial cells NIH-3T3) (Fig. 1). This was largely
seen across all of the time points measured, with some small
variations at 96 h. The images captured reflected what was
measured by the fluorescence, with large numbers of the cells
Scheme 1 Polyoxazoline synthesis route.
Table 1 Polyethylene glycol and polyoxazoline characteristics
Sample
Yield
[%]
DP
(theor.)
DP
(NMR)
Mn (GPC)
kDa
PDI
(GPC)
HOOC-PMOx-OMe (1a) 89 23 24 2.2 1.09
HOOC-PEOx-OMe (1b) 83 20 23 2.1 1.08
HOOC-PEG-OMea (1c) — 45 44 2.1 1.06
HOOC-PEsterOx-
COOMe (1d)b
90 14 16 3.1 1.12
a Commercially available PEG (Iris Biotech). b Bimodal by aqueous
GPC.
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undergoing apoptosis for the unmodified dendrimer, whilst
the cells incubated with the modified dendrimers were similar
in appearance to the saline control. The modification of the
dendrimer with POZ and PEG had removed and masked some
of the cationic charge from the surface of the dendrimer and
provided a barrier to membrane disruption, which was consist-
ent with previously reported studies.27
Blood compatibility studies were performed on the various
modified dendrimers. Firstly, haemolysis experiments were
performed, which was a measurement of the haemoglobin
(Hb) released by the red blood cells after rupture of the cell.
The results showed that the PEG and POZ modified dendri-
mers were found to be non-haemolytic (ESI Fig. 20†) where the
haemoglobin measured was lower than the limit of detection
for the instrument (<0.3 g dl−1). Only a small amount of
haemolysis (2.45 g dl−1) was observed for the unmodified den-
drimer but this was mainly due to the aggregation of the blood
cells. The second experiment for blood compatibility was red
blood cell aggregation, and was determined though
microscopy. The unmodified lysine dendrimer caused severe
Table 2 Unmodified and modified dendrimer characteristics
Sample description
Yield
[%]
Estimated no. of substituted
amines (1H NMR)
Mn (kg mol
−1)
(GPC)
PDI
(GPC)
RD (nm)
(GPC)
RD (nm)
(DLS)a
Zeta potential
(DLS)
G5-PLL-NH2 — — ND ND ND ND 32.1 ± 5.07
G5-PLL[PMOx]x[NH2]y (2a) 70 35 79.5 1.06 10.9 9.04 3.2 ± 6.80
G5-PLL[PEOx]x[NH2]y (2b) 69 38 100.0 1.05 11.8 10.24 2.76 ± 4.26
G5-PLL[PEG]x[NH2]y (2c) 79 30 80.7 1.09 14.0 14.54 −0.514 ± 3.92
G5-PLL[PEster]x[NH2]y (2d) 82 28 ND ND ND 8.56 10.3 ± 5.41
G5-PLL[PEster]x[COOH]y (3d) 94 64
c ND ND ND 7.87 −12.1 ± 5.63
G5-PLL[PAcid]x[COOH]y (4d) 89 64
c 117.2 1.04 12.6 6.73 (8.93b) −36 ± 12.2
ND = not determined. a Volume average. bMeasured in GPC eluent (40 : 10 mM NaNO3 : NaH2PO4 in water).
c Remaining amines were modified
with succinic anhydride.
Fig. 1 Cell apoptosis studies. Graph showing relative apoptosis (measured by fluorescence and compared to unmodified dendrimer at 96 h over
various time points). Right showing representative images of the cells at 24 h.
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aggregation of the red blood cells forming a continous
network of red blood cells (Fig. 2). The POZ and PEG modified
dendrimers did not cause any observable aggregation of the
red blood cells and looked consistent with the saline control.
The concentrations for the blood compatibility and cytotoxicity
were chosen to reflect a scenario of an IV administered dendrimer
at a reasonable dose of 50 mg kg−1 in mouse. The hypothesis
being that a mouse weighing 30 g would receive approximately
1.5 mg of polymer per dose and therefore initial concentrations
would be highest in plasma followed by dilution and distri-
bution/clearance to give lower final tissue concentrations.
Coumarin loading onto POZ modified dendrimers. A deriva-
tive of coumarin with a primary amine attachment point was
used as a model compound to conjugate to the dendrimers.
This compound offered the benefit of a stable amide bond to
the dendrimer to aid with the purification and analysis. The
aromatic protons made the quantification of the loading
straightforward by 1H NMR since there are no other interfering
signals from the dendrimer in this region. Here we wanted to
show that by adapting the main-chain functionality of the POZ
from a simple alkyl group into a useful moiety (carboxyl
groups) there could be significantly more sites available for
conjugation and therefore could achieve higher loading. The
remaining lysine amines on the POZ modified dendrimers (2a
and 2d) were reacted with succinic anhydride to convert them
into carboxyl groups (dendrimers 3a and 3d). Polymer 3d then
underwent a mild methyl ester deprotection step using LiOH
in MeOH/H2O overnight to convert the main-chain esters into
carboxyl groups to generate further sites for conjugation of the
coumarin (polymer 4d). Whilst the PMOx modified dendrimer
(3a) had ∼32 theoretical sites on the dendrimer for conju-
gation of courmarin, the carboxyl-functional POZ dendrimer
(4d) had ∼576 (18× more). However, it is well known in a drug
delivery scenario that overloading polymeric carriers with
hydrophobic species can lead to solubility problems/aggrega-
tion in solution. Therefore, we aimed to modify a conservative
30% of the carboxyl groups (173 sites). The conjugation of cou-
marin to the dendrimers was performed using DMTMM·BF4 in
anhydrous DMF using a slight excess of the coumarin for
polymer 3a 40 molecules per dendrimer, 1.25 eq.) and the
intended 173 molecules per dendrimer for polymer 4d. The
loadings of coumarin were measured using 1H NMR (Fig. 3).
The loadings were found to be 6.4 wt% (25 molecules per
dendrimer) for the PMOx modified dendrimer and 31 wt%
(166 molecules per dendrimer) for the carboxyl-functionalized
dendrimer (6.6× more loading). To determine whether the
high coumarin loading on 4d (resultant polymer 5d) had
induced the formation of aggregates and micellar structures,
Fig. 2 Blood compatibility aggregation study of unmodified versus PEG and PEOx modified dendrimers (a = saline, b = unmodified dendrimer, c =
PEG modified and d = PEOx modified).
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DLS was performed. For the polymer conjugate derived from
the PMOx modified dendrimer 4a (25 coumarin molecules)
there was no observable change to the size distribution (ESI
Fig. 21†). For the coumarin loaded carboxyl-functional dendri-
mer, 5d there was a small reduction in hydrodynamic volume
accompanied with a tail of larger particle sizes observed in the
size distribution when compared to the precursor (ESI
Fig. 22†). However, when repeated in a more appropriate
buffer (as for GPC) this was not observed (ESI Fig. 23†). The
absence of higher molecular weight species was strengthened
from the GPC data where no aggregation or larger particles
were observed in the light scattering (ESI Fig. 24†).
Clinically, high drug loading on drug delivery systems is
desirable. Historically many polymer-drug conjugates have
suffered from low drug loading and typically have less than
10% by weight active compound (e.g. HPMA-Doxorubicin, PK1
and PEG-Camptothecin, PROTHECAN).28 Low drug loading
drives the need for very potent drug molecules, which are not
always possible or desirable. Alternatively, large amounts of
the nano-carrier are required often resulting in high number
of nanoparticles dosed per injection. Both the quantity of
nano-carrier and the number of particles being dosed carry a
toxicity risk, either from the material itself or excessively large
numbers of nanoparticles. More extensive pre-clinical toxicity
studies will be required if a clinically unprecedented concen-
tration of materials is dosed and regulatory hurdles will be
higher. Additionally, from a practical perspective, in pre-
clinical development where injection volume is limited to
5 mL kg−1 in many species, doses may be limited due to solu-
bility or physical stability issues. Similarly in the clinic, low
drug loading can result in large volumes or a large number of
vials with additional challenges to patient, clinical staff and
costs. Many of the polymers used in polymer therapeutics are
bespoke and are therefore expensive with often non-standard
and extensive characterisation requirements to ensure quality
and reproducible in vivo performance, thus, minimising quan-
tities from a cost of goods perspective will be desirable. There-
fore nano-carriers such as the dendrimers described in this
paper with the capacity for considerably higher drug loading
and considering the amount required to deliver 100 mg dose
(in man) provide a more efficient delivery system and therefore
have benefits in terms of development and commercialisation
and patient/clinician acceptability.
Conclusions
Polyoxazolines have already shown great promise in the field
of polymer therapeutics and we wanted to extend their use to
coating materials for L-lysine dendrimers. Three different poly-
Fig. 3 1H NMR (400 MHz, D2O) spectra for the coumarin conjugated POZ dendrimers showing 6.4 wt% loading for PMOx modified dendrimer and
31 wt% loading for the carboxyl functional POZ dendrimer.
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oxazolines were synthesised with average molecular weights in
the region of 2000 g mol−1 to compare with a commercial
methoxy-PEG. A generation 5 L-lysine dendrimer was then
modified with these chain-end functional POZs and PEG
though an amide coupling step. We demonstrated that the
PMOx and PEOx coated lysine dendrimers have similar pro-
perties to the PEG coated equivalent but with slightly lower
hydrodynamic diameters. We imagined that one major benefit
of POZ over PEG came from the mainchain functionality that
it could offer and therefore a POZ with main-chain ester func-
tionalities was synthesized and used to modify the dendrimer,
which were subsequently deprotected to give carboxyl groups.
Whilst the PEG and PMOx dendrimers with 50% coating modi-
fication were limited to ∼32 coumarin molecules per dendri-
mer, the novel carboxyl functional POZ coating had the
potential to hold up to ∼576, albeit that a rational choice to
prevent aggregation was to conjugate coumarin to only 30% of
these (173 molecules). The use of a carboxyl-functional POZ
has provided a novel approach for generating large numbers of
conjugation sites for drug molecules to improve the loading,
whilst other approaches have been limited by the residual
surface functional groups from the ultimate generation of the
dendrimer itself.
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